1. Inici
  2. Publicacions
  3. Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction

Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Franco, J
  • Formiga, F
  • Cepeda, J
  • Arevalo-Lorido, J
  • Cerqueiro, J
  • Gonzalez-Franco, A
  • Epelde, F
  • Manzano, L
  • Montero Pérez-Barquero M
  • Grupo de investigadores RICA

Abstract

Introduction and objectives: The impact of atrial fibrillation (AF) on the prognosis of heart failure with preserved ejection fraction (HFpEF) is still the subject of debate. We analysed the influence of AF on the prognosis on mortality and readmission in patients with HFpEF. Methods: Prospective observational study in 1,971 patients with HFpEF, who were admitted for acute heart failure. Patients were divided into 2 groups according to the presence or absence of AF. We analysed mortality, readmissions and combined mortality/readmissions at one year follow-up. Results: A total of 1,177 (59%) patients had AF, mean age 80.3 (7.8) years and 1,233 (63%) were women. Patients with HFpEF and AF were older, female, greater valvular aetiology and lower comorbidity measured by the Charlson index. At the one year follow-up, 430 (22%) patients had died and 840 (43%) had been readmitted. In the 2 groups analysed, there was no difference in all-cause mortality (22 vs. 21%; P= .739, AF vs. no-AF, respectively) or cardiovascular causes (9.6 vs. 8.2%; P = .739, AF vs. no-AF, respectively). In the multivariable analysis, factors associated with higher mortality were: age, male, valvular aetiology, uric acid, and comorbidity. In the analysis of the subgroup with HFpEF with AF, the presence of chronic AF compared to de novo AF was associated with higher mortality (HR 1,716; 95% CI 1,099-2,681; P = .018). Conclusions: In patients with HFpEF, the presence of AF is frequent. During the one-year follow-up, the presence of AF does not influence mortality or readmissions in patients with HFpEF. (C) 2017 Elsevier Espana, S.L.U. All rights reserved.

Dades de la publicació

ISSN/ISSNe:
0025-7753, 1578-8989

MEDICINA CLINICA  ELSEVIER DOYMA SL

Tipus:
Article
Pàgines:
376-382
PubMed:
28870424
Factor d'Impacte:
0,220 SCImago ℠
Quartil:
Q3 SCImago ℠

Cites Rebudes en Web of Science: 7

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Heart failure; Preserved ejection fraction; Atrial fibrillation; Mortality; Hospital readmission

Campos d'Estudi

Projectes associats

ESTUDIO MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO PARA EVALUAR EL EFECTO DE SERELAXINA COMPARADO CON EL TRATAMIENTO DE REFERENCIA EN PACIENTES CON INSUFICIENCIA CARDÍACA AGUDA (ICA).

Investigador Principal: PAU LLACER IBORRA

CRLX030A3301 . 2014

ENSAYO ALEATORIZADO CONTROLADO SOBRE LA TERAPIA GUIADA POR EL ANTÍGENO CARBOHIDRATO 125 EN LOS PACIENTES DADOS DE ALTA POR INSUFICIENCIA CARDIACA AGUDA: EFECTO SOBRE LA MORTALIDAD O REINGRESO POR INSUFICIENCIA CARDIACA A 1 AÑO.

Investigador Principal: PAU LLACER IBORRA

CHANCE-HF . 2013

DOSIFICACIÓN DE LOS DIURÉTICOS DE ASA EN PACIENTES CON INSUFICIENCIA CARDIACA AGUDA E INSUFICIENCIA RENAL: ESTRATEGIA CONVENCIONAL VERSUS ESTRATEGIA GUIADA POR LOS NIVELES PLASMÁTICOS DEL ANTÍGENO CARBOHIDRATO 125.

Investigador Principal: PAU LLACER IBORRA

IMPROVE-AHF

Compartir la publicació